

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/765,692	. <u> </u>	01/27/2004	Robert A. Holton	FSUM 10468.2	1424
321	7590	06/22/2004		EXAMINER	
		RS LEAVITT ANI	OWENS, AMELIA A		
ONE METROPOLITAN SQUARE 16TH FLOOR ST LOUIS, MO 63102				ART UNIT	PAPER NUMBER
				1625	

DATE MAILED: 06/22/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/765,692	HOLTON ET AL.					
Office Action Summary	Examiner	Art Unit					
	Amelia A. Owens	1625					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tin y within the statutory minimum of thirty (30) day vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on	⊶						
2a) This action is FINAL . 2b) ⊠ This	action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) <u>1-13</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) <u>1-13</u> is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	wn from consideration.						
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Ex							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	r (PTO-413) ate Patent Application (PTO-152)					

Ī

Application/Control Number: 10/765,692

Art Unit: 1625

DETAILED ACTION

Claims 1-13 are pending. No drawings were filed with the application.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on January 27, 2004 has been considered by the examiner.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-13 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-31 of U.S. Patent No. 6,066,747. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are directed to the same generic concept.

See claim 1 where the positions R1 = OH, R9a = beta-OH, R10 = H; the positions R4a, R7a, R10a, R14 overlap; and the positions R2, R13, R28 thru R31 are identical. This gives the compounds that correspond to the claimed invention.

Application/Control Number: 10/765,692

Art Unit: 1625

See claim 18 where the positions R1 = OH, R9a = beta-OH, R10 = H; the positions R2, R4a, R7a, R10a, R14 overlap; and the positions R13, R28 thru R31 are identical. This gives compounds that correspond to the claimed invention.

See claim 25 where the positions R1 = OH, R9a = beta-OH, R10 = H; the positions R2, R4a, R7a, R10a overlap; and the positions R13, R14, R28 thru R31 are identical. This gives compounds that correspond to the claimed invention.

Claims 1-13 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 12-13 of U.S. Patent No. 6,495,704 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are directed to the same generic concept.

See claim 12 where the positions R1/R10a = OH; R2a/R5/R6/R6a/R7/R9/R10/R14/R14a = H; R4/R5a form oxetane ring, R9a = beta-OH; the positions R2, R7a overlap; and the positions R4a, R13, R14, R28 thru R31 are identical. This gives compounds that correspond to the claimed invention.

See claim 13 where the position R14 =H; and the positions R2, R4a, R7a, R10a, R13, R28 thru R31 are identical. This gives compounds that correspond to the claimed invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amelia A. Owens whose telephone number is 571-272-0690. The examiner can normally be reached on Monday - Friday from 8:30 - 5:00.

Art Unit: 1625

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amelia A. Owens Primary Examiner

Art Unit 1625